In vitro and in vivo synergy of fosmidomycin, a novel antimalarial drug, with clindamycin.
about
Assessment of the pharmacokinetics and dynamics of two combination regimens of fosmidomycin-clindamycin in patients with acute uncomplicated falciparum malariaFosmidomycin plus clindamycin for treatment of pediatric patients aged 1 to 14 years with Plasmodium falciparum malariaThe heat shock protein 90 of Plasmodium falciparum and antimalarial activity of its inhibitor, geldanamycinLeveraging structure determination with fragment screening for infectious disease drug targets: MECP synthase from Burkholderia pseudomalleiNew N-Acetyltransferase Fold in the Structure and Mechanism of the Phosphonate Biosynthetic Enzyme FrbFCytidine derivatives as IspF inhibitors of Burkolderia pseudomalleiA chemical rescue screen identifies a Plasmodium falciparum apicoplast inhibitor targeting MEP isoprenoid precursor biosynthesisFragment screening of infectious disease targets in a structural genomics environmentActivity of Ocimum basilicum, Ocimum canum, and Cymbopogon citratus essential oils against Plasmodium falciparum and mature-stage larvae of Anopheles funestus s.s.Short-course regimens of artesunate-fosmidomycin in treatment of uncomplicated Plasmodium falciparum malaria.Plasmodium chloroquine resistance and the search for a replacement antimalarial drug.Additive in vitro antiplasmodial effect of N-alkyl and N-benzyl-1,10-phenanthroline derivatives and cysteine protease inhibitor e64.Antiapicoplast and gametocytocidal screening to identify the mechanisms of action of compounds within the malaria box.Andrographolide: A Novel Antimalarial Diterpene Lactone Compound from Andrographis paniculata and Its Interaction with Curcumin and Artesunate.Sub-inhibitory fosmidomycin exposures elicits oxidative stress in Salmonella enterica serovar Typhimurium LT2.Trioxaquines are new antimalarial agents active on all erythrocytic forms, including gametocytesRandomized controlled trial of fosmidomycin-clindamycin versus sulfadoxine-pyrimethamine in the treatment of Plasmodium falciparum malariaPharmacokinetics and pharmacodynamics of fosmidomycin monotherapy and combination therapy with clindamycin in the treatment of multidrug resistant falciparum malariaIn vivo antimalarial activity of the endophytic actinobacteria, Streptomyces SUK 10.Inadequate efficacy of a new formulation of fosmidomycin-clindamycin combination in Mozambican children less than three years old with uncomplicated Plasmodium falciparum malaria.Parasite plastids: approaching the endgame.The plastid-derived organelle of protozoan human parasites as a target of established and emerging drugs.Antimalarial drugs: current status and new developments.The global pipeline of new medicines for the control and elimination of malariaA systems biology approach to uncovering pharmacological synergy in herbal medicines with applications to cardiovascular disease.Plasmodium IspD (2-C-Methyl-D-erythritol 4-Phosphate Cytidyltransferase), an Essential and Druggable Antimalarial Target.Selective inhibition of E. coli 1-deoxy-D-xylulose-5-phosphate synthase by acetylphosphonates().Update on clindamycin in the management of bacterial, fungal and protozoal infections.Anti-malarial activities of Andrographis paniculata and Hedyotis corymbosa extracts and their combination with curcuminSystems pharmacology exploration of botanic drug pairs reveals the mechanism for treating different diseases.Haemoglobin interference and increased sensitivity of fluorimetric assays for quantification of low-parasitaemia Plasmodium infected erythrocytesGancidin W, a potential low-toxicity antimalarial agent isolated from an endophytic Streptomyces SUK10In vitro synergistic effect of amphotericin B and allicin on Leishmania donovani and L. infantum.Isoprenoid biosynthesis in the erythrocytic stages of Plasmodium falciparum.Emerging drugs for malaria.New approaches in antimalarial drug discovery and development: a review.Natural product and natural product derived drugs in clinical trials.New insight-guided approaches to detect, cure, prevent and eliminate malaria.Fosmidomycin as an antimalarial drug: a meta-analysis of clinical trials.Whole-Genome Sequencing to Evaluate the Resistance Landscape Following Antimalarial Treatment Failure With Fosmidomycin-Clindamycin.
P2860
Q21034149-8E891EE0-2D0A-4E9D-A4EC-A30607F3C1D7Q24680404-06D5038B-2C05-43B2-A299-E0866B6CB46EQ24802251-B02844F5-FE06-4755-8848-2D618E439097Q27667103-D271A2BA-373B-4B1C-A663-FD416B7B913AQ27671948-18983B4B-C0F9-4D9C-843B-2FD7B30E5D5AQ27680454-BFF34F04-BDB3-4E57-B066-B62E6E4D5BDBQ30043334-2CC56CF8-620F-4D92-ABFB-C8DC14F47138Q33836468-93964CA5-4B99-49D8-A22A-4D9CE717979DQ33847379-18E0B09E-A2EB-4512-94CA-A85EF2513412Q33935493-3EB7D602-B160-4D8E-A307-60FBC8D96153Q34153077-62E71DE8-F2C2-44A3-B678-4D538CC923AAQ34158257-9C61CC71-0E4F-4827-8733-4E806ABFA964Q35046030-A6EB8837-A6AB-4D5D-A837-4C09545AA923Q35098931-CA30F1AF-7C21-4DA2-92A0-2C79252E7FE9Q35153938-C5FEACF6-0365-4482-A581-3D52C18C18DFQ35758958-6CD36D4F-1CDA-45B3-B0AC-CEDC5F955057Q35759028-41B727F0-AF39-4BFB-9246-0F88B38E7ADEQ35850868-AB7A6A4E-1171-45D8-B485-9A7E7E67BE7BQ35857660-E5583F3E-3BC0-4891-A291-54492FA15A77Q36018812-6CFF33C2-A8DD-4A49-BE15-4D59AB673EE7Q36052586-3DFC9F2E-2861-4207-A171-5B9E1F88778AQ36066272-3F369583-A396-467E-B5D4-16F1E27C1A1DQ36196479-13F0777E-69CC-4872-84CD-DC59F967EE34Q36320249-974A031E-A7BF-41CC-BBE3-6FB1372F7E5FQ36457923-B8924BAB-4122-4AA2-8071-350ABD81774FQ36467783-D6CC02B1-E210-4FB0-8A56-78AF856A70ACQ36529354-44B63BD7-FF31-43A4-8E2B-875DBB977C1BQ36967293-E7E28D67-F382-4B90-92BA-BAAC065C63FCQ37116119-960D32DC-0E58-4EA7-9CE2-815A58945379Q37411758-5AFE64F0-C386-4B93-8D11-A4F6194B2792Q37479816-50AE00D6-3805-4B87-A020-2DD16C99A61DQ37641492-D122B409-D16D-4714-B481-4D3E26F407BEQ37643719-66CA8385-1587-4FA9-9BFB-894D3E5FF1F0Q37924610-EFE00108-AE12-4424-A54F-77EF78660591Q38027179-703DC529-E177-4A14-BAD1-B7FC6D4BBCC6Q38059380-5559E6BF-F070-41CB-84E4-7CAD85462220Q38247457-25976935-BAA2-4F1E-A348-B7628BA6326DQ38260909-CC91C06C-A5E0-4435-84A1-41C7FB4E0B8BQ38558100-DAC33A5A-C380-4FB1-A10C-EC1A16045930Q38839163-E70387D8-0308-4E4D-8CD3-4669B0009F5F
P2860
In vitro and in vivo synergy of fosmidomycin, a novel antimalarial drug, with clindamycin.
description
2002 nî lūn-bûn
@nan
2002 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
In vitro and in vivo synergy o ...... larial drug, with clindamycin.
@ast
In vitro and in vivo synergy o ...... larial drug, with clindamycin.
@en
In vitro and in vivo synergy o ...... larial drug, with clindamycin.
@nl
type
label
In vitro and in vivo synergy o ...... larial drug, with clindamycin.
@ast
In vitro and in vivo synergy o ...... larial drug, with clindamycin.
@en
In vitro and in vivo synergy o ...... larial drug, with clindamycin.
@nl
prefLabel
In vitro and in vivo synergy o ...... larial drug, with clindamycin.
@ast
In vitro and in vivo synergy o ...... larial drug, with clindamycin.
@en
In vitro and in vivo synergy o ...... larial drug, with clindamycin.
@nl
P2093
P2860
P1476
In vitro and in vivo synergy o ...... larial drug, with clindamycin.
@en
P2093
Dajana Henschker
David B Hutchinson
Ewald Beck
Hassan Jomaa
Jochen Wiesner
P2860
P304
P356
10.1128/AAC.46.9.2889-2894.2002
P407
P577
2002-09-01T00:00:00Z